Bioprocessing Pionee | Repligen leads the $12B bioprocessing market with innovative technologies, strategic acquisitions, and a focus on new modalities driving growth |
Financial Resilience | Despite market challenges, Repligen maintains strong financials with a 51.15% gross profit margin and upward revenue guidance for 2025 |
Market Dominance | Explore Repligen's unique position, with 80% of its portfolio facing little to no competition, fostering pricing power and market leadership |
Future Trajectory | Analyst targets range from $150 to $220, reflecting varied views on Repligen's growth potential amid industry recovery and expansion |
Metrics to compare | RGEN | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipRGENPeersSector | |
|---|---|---|---|---|
P/E Ratio | 5,388.1x | 25.5x | −0.6x | |
PEG Ratio | 45.83 | 0.00 | 0.00 | |
Price/Book | 4.5x | 2.7x | 2.6x | |
Price / LTM Sales | 13.2x | 3.5x | 3.2x | |
Upside (Analyst Target) | 14.2% | 17.2% | 41.8% | |
Fair Value Upside | Unlock | 5.5% | 5.1% | Unlock |